Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Specialty Chemicals

Avantor, Inc. provides products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries worldwide. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, and clinical trial kits. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Website: avantorsciences.com



Growth: Bad revenue growth rate -5.6%, there is slowdown compared to average historical growth rates 1.6%. The revenue growth dynamics is unstable Site traffic for the last 3 months showed a change of -18.1%

Profitability: LTM EBITDA margin is positive, +14.7%. On average the margin is decreasing unsteadily. Gross margin is normal, +34.0%. In the last quarter the company beat the estimated EPS, +3.6%. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.01 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 4.1% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 44.1% higher than minimum and 43.8% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 2.2x by EV / Sales multiple , the company can be 31.2% overvalued

Insiders: For the last 3 months insiders sold company shares on $0.7 mln (-0.004% of cap.)

Key Financials (Download financials)

Ticker: AVTR
Share price, USD:  (0.0%)24.72
year average price 21.89  


year start price 20.09 2023-05-08

min close price 17.15 2023-10-30

max close price 26.07 2024-03-22

current price 24.72 2024-05-06
Common stocks: 672 901 589

Dividend Yield:  0.0%
FCF Yield LTM: 4.1%
EV / LTM EBITDA: 21.5x
EV / EBITDA annualized: 22.1x
Last revenue growth (y/y):  -5.6%
Last growth of EBITDA (y/y):  -25.9%
Historical revenue growth:  1.6%
Historical growth of EBITDA:  32.9%
EV / Sales: 3.2x
Margin (EBITDA LTM / Revenue): 14.7%
Fundamental value created in LTM:
Market Cap ($m): 16 634
Net Debt ($m): 5 129
EV (Enterprise Value): 21 763
Price to Book: 3.1x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-04-29Zacks Investment Research

Avantor (AVTR) Q1 Earnings Surpass Estimates, Margins Down

2024-04-25Zacks Investment Research

Is a Surprise Coming for Avantor (AVTR) This Earnings Season?

2024-04-25Zacks Investment Research

ELV or AVTR: Which Is the Better Value Stock Right Now?

2024-04-08Zacks Investment Research

BLCO vs. AVTR: Which Stock Is the Better Value Option?

2024-03-26Zacks Investment Research

Three Reasons to Retain Avantor (AVTR) Stock in Your Portfolio

2024-03-21Zacks Investment Research

BLCO or AVTR: Which Is the Better Value Stock Right Now?

2024-02-20Zacks Investment Research

New Strong Sell Stocks for February 20th

2024-02-15Zacks Investment Research

Avantor (AVTR) Q4 Earnings & Revenues Top Estimates, Margins Down

2024-02-14Zacks Investment Research

Compared to Estimates, Avantor, Inc. (AVTR) Q4 Earnings: A Look at Key Metrics

2024-02-09Zacks Investment Research

Curious about Avantor, Inc. (AVTR) Q4 Performance? Explore Wall Street Estimates for Key Metrics
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol AVTR AVTR AVTR AVTR AVTR AVTR AVTR
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-04-26 2024-02-14 2023-10-27 2023-07-28 2023-04-28 2023-02-14 2022-10-28
acceptedDate 2024-04-26 09:00:04 2024-02-14 07:09:38 2023-10-27 09:11:07 2023-07-28 09:06:06 2023-04-28 09:02:26 2023-02-14 16:08:19 2022-10-28 09:06:25
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 1 680M 1 723M 1 720M 1 744M 1 780M 1 795M 1 857M
costOfRevenue 1 109M 1 152M 1 142M 1 154M 1 156M 1 181M 1 206M
grossProfit 571M 570M 579M 590M 625M 615M 651M
grossProfitRatio 0.340 0.331 0.336 0.338 0.351 0.342 0.350
researchAndDevelopmentExpenses 0 0 0 0 0 0 0
generalAndAdministrativeExpenses 0 0 0 0 0 352M 0
sellingAndMarketingExpenses 0 0 0 0 0 11M 0
sellingGeneralAndAdministrativeExpenses 401M 387M 368M 358M 394M 363M 375M
otherExpenses 300 000 2M 700 000 2M 600 000 -6M 0
operatingExpenses 401M 387M 368M 358M 394M 363M 375M
costAndExpenses 1 510M 1 540M 1 510M 1 511M 1 549M 1 543M 1 581M
interestIncome 0 0 72M 0 0 0 0
interestExpense 64M 65M 72M 73M 74M 70M 67M
depreciationAndAmortization 100M 101M 98M 103M 102M 95M 100M
ebitda 269M 286M 309M 337M 333M 347M 376M
ebitdaratio 0.160 0.166 0.180 0.193 0.187 0.193 0.203
operatingIncome 170M 183M 210M 72M 231M 252M 276M
operatingIncomeRatio 0.101 0.106 0.122 0.041 0.130 0.140 0.149
totalOtherIncomeExpensesNet -89M 2M -1M -160M -75M -77M -68M
incomeBeforeTax 81M 120M 137M -1M 156M 175M 208M
incomeBeforeTaxRatio 0.048 0.069 0.079 -0.001 0.088 0.097 0.112
incomeTaxExpense 20M 21M 28M 6M 34M 33M 41M
netIncome 60M 99M 108M -7M 122M 142M 167M
netIncomeRatio 0.036 0.057 0.063 -0.004 0.068 0.079 0.090
eps 0.089 0.150 0.160 -0.011 0.180 0.210 0.250
epsdiluted 0.089 0.140 0.160 -0.011 0.180 0.210 0.250
weightedAverageShsOut 678M 676M 676M 675M 675M 674M 674M
weightedAverageShsOutDil 681M 679M 679M 675M 678M 677M 679M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol AVTR AVTR AVTR AVTR AVTR AVTR AVTR
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-04-26 2024-02-14 2023-10-27 2023-07-28 2023-04-28 2023-02-14 2022-10-28
acceptedDate 2024-04-26 09:00:04 2024-02-14 07:09:38 2023-10-27 09:11:07 2023-07-28 09:06:06 2023-04-28 09:02:26 2023-02-14 16:08:19 2022-10-28 09:06:25
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 235M 263M 237M 236M 295M 373M 266M
shortTermInvestments 18M 17M 28M 0 0 0 0
cashAndShortTermInvestments 235M 263M 237M 236M 295M 373M 266M
netReceivables 1 130M 1 150M 1 150M 1 216M 1 277M 1 218M 1 231M
inventory 811M 828M 850M 890M 904M 914M 905M
otherCurrentAssets 146M 144M 147M 156M 152M 153M 158M
totalCurrentAssets 2 321M 2 385M 2 385M 2 499M 2 627M 2 658M 2 560M
propertyPlantEquipmentNet 740M 738M 698M 698M 737M 727M 698M
goodwill 5 672M 5 717M 5 638M 5 694M 5 683M 5 653M 5 511M
intangibleAssets 3 663M 3 775M 3 788M 3 895M 4 077M 4 133M 4 099M
goodwillAndIntangibleAssets 9 335M 9 492M 9 426M 9 589M 9 760M 9 786M 9 610M
longTermInvestments 24M 67M -649M -663M 0 0 0
taxAssets 601M -67M 649M 663M 696M 0 0
otherNonCurrentAssets -257M 358M 289M 277M -423M 294M 245M
totalNonCurrentAssets 10 442M 10 588M 10 413M 10 564M 10 769M 10 806M 10 553M
otherAssets 0 0 0 0 0 0 0
totalAssets 12 763M 12 973M 12 798M 13 063M 13 396M 13 464M 13 113M
accountPayables 573M 626M 656M 687M 766M 758M 769M
shortTermDebt 299M 260M 336M 314M 325M 364M 281M
taxPayables 0 0 0 0 0 0 0
deferredRevenue 0 183M 160M 174M 0 731M 0
otherCurrentLiabilities 569M 411M 337M 376M 579M -195M 502M
totalCurrentLiabilities 1 442M 1 480M 1 488M 1 550M 1 670M 1 659M 1 552M
longTermDebt 5 024M 5 277M 5 291M 5 570M 5 736M 5 923M 5 908M
deferredRevenueNonCurrent 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 601M 613M 649M 663M 696M 731M 728M
otherNonCurrentLiabilities 361M 350M 271M 269M 300M 295M 5 921M
totalNonCurrentLiabilities 5 985M 6 240M 6 211M 6 502M 6 732M 6 950M 6 970M
otherLiabilities 0 0 0 0 0 0 0
capitalLeaseObligations 68M 151M 68M 0 0 0 0
totalLiabilities 7 427M 7 720M 7 699M 8 052M 8 401M 8 609M 8 522M
preferredStock 0 0 0 0 0 -1 070M 0
commonStock 3 881M 3 830M 3 818M 3 799M 3 792M 3 785M 3 775M
retainedEarnings 1 552M 1 492M 1 393M 1 285M 1 292M 1 170M 1 029M
accumulatedOtherComprehensiveIncomeLoss -97M -69M -111M -72M -90M -100M -212M
othertotalStockholdersEquity 0 0 0 0 0 1 070M 0
totalStockholdersEquity 5 336M 5 253M 5 099M 5 011M 4 995M 4 855M 4 591M
totalEquity 5 336M 5 253M 5 099M 5 011M 4 995M 4 855M 4 591M
totalLiabilitiesAndStockholdersEquity 12 763M 12 973M 12 798M 13 063M 13 396M 13 464M 13 113M
minorityInterest 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 12 763M 12 973M 12 798M 13 063M 13 396M 13 464M 13 113M
totalInvestments 24M 67M -649M -663M 0 0 0
totalDebt 5 323M 5 537M 5 626M 5 884M 6 061M 6 288M 6 188M
netDebt 5 088M 5 274M 5 389M 5 648M 5 767M 5 915M 5 923M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol AVTR AVTR AVTR AVTR AVTR AVTR AVTR
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-04-26 2024-02-14 2023-10-27 2023-07-28 2023-04-28 2023-02-14 2022-10-28
acceptedDate 2024-04-26 09:00:04 2024-02-14 07:09:38 2023-10-27 09:11:07 2023-07-28 09:06:06 2023-04-28 09:02:26 2023-02-14 16:08:19 2022-10-28 09:06:25
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome 60M 99M 108M -7M 122M 142M 167M
depreciationAndAmortization 100M 101M 98M 103M 101M 101M 101M
deferredIncomeTax -18M -78M -29M -38M -26M -7M -22M
stockBasedCompensation 13M 9M 10M 9M 13M 10M 12M
changeInWorkingCapital -48M 97M 23M -92M -11M -64M -22M
accountsReceivables 3M 22M 47M 60M -52M 54M -800 000
inventory -11M 21M 11M -9M 7M 2M -21M
accountsPayables -44M -44M -21M -75M 600 000 -50M -7M
otherWorkingCapital 4M 98M -14M -69M 34M -70M 7M
otherNonCashItems 299M 25M 21M 194M 22M 25M 23M
netCashProvidedByOperatingActivities 142M 252M 231M 168M 220M 206M 258M
investmentsInPropertyPlantAndEquipment -35M -51M -38M -30M -28M -34M -39M
acquisitionsNet 0 -5M 0 0 -15M 0 0
purchasesOfInvestments 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 -43M 43M
otherInvestingActivites 500 000 6M 700 000 700 000 16M 43M -38M
netCashUsedForInvestingActivites -34M -50M -37M -29M -27M -33M 4M
debtRepayment -169M -188M -198M -191M -270M -164M -259M
commonStockIssued 46M -6M 9M 0 6M 0 0
commonStockRepurchased -7M -200 000 -200 000 -5M -8M -100 000 -100 000
dividendsPaid 0 0 0 0 -16M -32M 0
otherFinancingActivites -7M 26M 9M -200 000 13M 115M 40M
netCashUsedProvidedByFinancingActivities -130M -184M -188M -196M -275M -82M -219M
effectOfForexChangesOnCash -6M 10M -5M -700 000 5M 18M -16M
netChangeInCash -28M 27M -100 000 -58M -78M 109M 27M
cashAtEndOfPeriod 235M 288M 261M 261M 319M 397M 288M
cashAtBeginningOfPeriod 263M 261M 261M 319M 397M 288M 261M
operatingCashFlow 142M 252M 231M 168M 220M 206M 258M
capitalExpenditure -35M -51M -38M -30M -28M -34M -39M
freeCashFlow 107M 201M 193M 138M 192M 172M 219M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Earning call transcript

2024 q1
2024-04-26 ET (fiscal 2024 q1)
2023 q4
2024-02-14 ET (fiscal 2023 q4)
2023 q3
2023-10-27 ET (fiscal 2023 q3)
2023 q2
2023-07-28 ET (fiscal 2023 q2)
2023 q1
2023-04-28 ET (fiscal 2023 q1)
2022 q4
2023-02-03 ET (fiscal 2022 q4)
2022 q3
2022-10-28 ET (fiscal 2022 q3)
2022 q2
2022-07-29 ET (fiscal 2022 q2)
2022 q1
2022-04-29 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-04-26 10:00 ET
Avantor® Reports First Quarter 2024 Results
2024-04-01 12:00 ET
Avantor® to Host First Quarter 2024 Earnings Call on Friday, April 26, 2024
2024-03-21 00:00 ET
Avantor Wins Five Prestigious Awards at Asia-Pacific Biopharma Excellence Awards 2024
2024-02-26 13:05 ET
Avantor® Celebrates Supplier Award Honorees at 2024 European Sales Conference
2024-02-20 13:05 ET
Avantor® to Participate in the 44th Annual TD Cowen Health Care Conference
2024-02-14 11:00 ET
Avantor® Reports Fourth Quarter and Full Year 2023 Results
2024-02-01 14:00 ET
Board Courage in Advancing Workplace Equity a Critical Component of Resilient Companies
2024-01-24 13:05 ET
Avantor® to Report Fourth Quarter and Full Year 2023 Earnings on Wednesday, February 14, 2024
2024-01-19 15:00 ET
Avantor® Recognizes Supplier Award Winners at 2024 Americas Sales Conference
2024-01-03 13:05 ET
Avantor® to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-07 21:30 ET
Avantor® Hosts Investor Day, Announces New Strategic Operating Model to Drive Growth and Productivity
2023-11-30 21:05 ET
Avantor® Receives Top Score on Human Rights Campaign Foundation's 2023-2024 Corporate Equality Index
2023-11-22 12:05 ET
Avantor® to Host Investor Day on December 8, 2023
2023-11-16 12:05 ET
Avantor® to Participate in the 6th Annual Evercore ISI HealthCONx Conference
2023-10-27 10:05 ET
Avantor® Reports Third Quarter 2023 Results
2023-10-25 19:50 ET
Banks and Their Boards Need a More Strategic Approach to Responding to Societal Challenges
2023-09-29 12:05 ET
Avantor® to Host Third Quarter 2023 Earnings Call on Friday, October 27, 2023
2023-09-26 11:35 ET
Avantor® Announces Ger Brophy to Retire in 2024; Benoit Gourdier Appointed EVP, Biopharma Production
2023-09-21 12:05 ET
Avantor® Announces New Scientific Advisory Board
2023-09-13 12:30 ET
TOMI Environmental Solutions Announces Partnership with Avantor Expanding Presence of SteraMist Use in Critical Controlled Environments
2023-09-07 11:05 ET
Avantor® Partners with Tobin Scientific to Provide End-to-End Solution for Research Lab Relocations, Sample Transport, and GMP Storage Services
2023-08-29 11:05 ET
Avantor® to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
2023-07-28 10:05 ET
Avantor® Reports Second Quarter 2023 Results
2023-07-17 12:05 ET
Avantor® Announces Plans for New and Expanded Bridgewater, N.J. Innovation Center
2023-07-13 12:30 ET
Avantor® Names R. Brent Jones as Chief Financial Officer
2023-07-11 04:00 ET
Avantor Inaugurates Expanded Singapore Hub
2023-06-29 12:05 ET
Avantor® to Host Second Quarter 2023 Earnings Call on Friday, July 28, 2023
2023-06-21 12:05 ET
Avantor® Launches Responsible Supplier Program
2023-05-23 12:05 ET
Avantor® Releases 2023 Science for Goodness Sustainability Report
2023-05-22 11:05 ET
Avantor® and Labguru Collaborate to Drive More Efficient Lab Buying Experience
2023-05-17 12:05 ET
Avantor® to Participate in Bernstein's 39th Annual Strategic Decisions Conference
2023-05-15 11:30 ET
Avantor® Announces CFO Transition
2023-05-03 11:05 ET
Avantor® to Participate in BofA Securities 2023 Health Care Conference
2023-04-28 10:05 ET
Avantor® Reports First Quarter 2023 Results
2023-04-18 12:05 ET
Avantor® Announces Supplier Award Winners at Americas Sales Conference
2023-04-04 12:05 ET
Avantor® to Host First Quarter 2023 Earnings Call on Friday, April 28, 2023
2023-04-03 02:53 ET
Avantor Named Best Bioprocessing Supplier in Cell and Gene Therapy at the Biopharma Excellence Awards India Edition
2023-03-16 00:00 ET
Avantor Named Best Bioprocessing Company in Chromatography at the Asia-Pacific Bioprocessing Excellence Awards
2023-02-28 21:05 ET
Avantor® to Present at Upcoming Investor Conferences
2023-02-03 11:05 ET
Avantor® Reports Fourth Quarter and Full-Year 2022 Results
2023-01-18 14:05 ET
Avantor® and Avantor Foundation Giving Supports Communities Around the Globe in 2022
2023-01-06 14:05 ET
Avantor® to Report Fourth Quarter and Full Year 2022 Earnings and Host Earnings Call on Friday, February 3, 2023
2023-01-03 14:05 ET
Avantor® to Participate in the 41st Annual J.P. Morgan Healthcare Conference
2022-11-15 14:05 ET
Avantor® to Participate in the 5th Annual Evercore ISI HealthCONx Conference
2022-11-03 13:05 ET
Avantor® Continues Investment to Support Biopharma Market with Opening of New Distribution Center in Dublin, Ireland
2022-10-28 10:05 ET
Avantor® Reports Third Quarter 2022 Results
2022-09-29 13:05 ET
Avantor® to Host Third Quarter 2022 Earnings Call on Friday, October 28, 2022
2022-08-30 13:05 ET
Avantor® to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
2022-08-23 23:00 ET
Avantor and Avantor Foundation Make a Difference by Providing Critical Health Services for Vulnerable Communities in Singapore
2022-07-28 20:05 ET
Avantor® Reports Second Quarter 2022 Results
2022-07-19 13:05 ET
Avantor® Names Kitty Sahin Executive Vice President, Strategy and Corporate Development
2022-06-30 13:05 ET
Avantor® to Host Second Quarter 2022 Earnings Call on Friday, July 29, 2022
2022-06-30 01:42 ET
Avantor Named Best Company for Upstream Processing and Single-Use Solutions at BMK 2022
2022-06-23 13:05 ET
Avantor® to Collaborate with GeminiBio to Bring Custom Hydrated Solutions and Cell Culture Media to Biopharma Customers
2022-06-01 13:05 ET
Avantor® to Participate in the 43rd Annual Goldman Sachs Global Healthcare Conference
2022-05-17 13:05 ET
Avantor® Releases 2022 Sustainability Report, Highlighting Significant Progress in Environmental, Social and Governance (ESG) Efforts
2022-05-13 20:05 ET
Avantor® Announces Conversion of Mandatory Convertible Preferred Stock
2022-05-12 20:05 ET
Jonathan Peacock Elected Chairman of the Board of Directors of Avantor®
2022-05-10 13:05 ET
Avantor® and Cytovance Biologics Collaborate to Accelerate Plasmid DNA Development for Biopharma Customers
2022-05-04 20:05 ET
Avantor® Announces Investment in Manufacturing and Distribution Hub in Singapore to Serve Rapidly Growing Asia Pacific Biopharma Industry
2022-05-04 19:05 ET
Avantor Announces Investment in Manufacturing and Distribution Hub in Singapore to Serve Rapidly Growing Asia Pacific Biopharma Industry
2022-04-28 20:05 ET
Avantor® Reports First Quarter 2022 Results
2022-04-26 13:05 ET
Avantor® to Participate in BofA Securities 2022 Healthcare Conference
2022-04-21 20:05 ET
Avantor® Declares Dividend on Mandatory Convertible Preferred Stock
2022-04-06 13:05 ET
Avantor® to Report First Quarter 2022 Results and Host Earnings Call on April 29, 2022
2022-03-08 14:05 ET
Avantor® to Participate in KeyBanc Life Sciences and Medtech Investor Forum
2022-03-03 14:05 ET
Avantor Foundation Giving Surpasses $6 Million Since Inception
2022-03-01 14:05 ET
Avantor® to Participate in Barclays Global Healthcare Conference 2022
2022-02-25 14:05 ET
Avantor® to Participate in 42nd Annual Cowen Healthcare Conference
2022-02-15 21:47 ET
Avantor® Announces Planned Retirement of Rajiv Gupta, Board Chairman
2022-02-11 14:30 ET
Avantor® Breaks Ground on New Distribution Center to Serve Growing Biopharmaceutical Industry in Ireland
2022-02-03 21:05 ET
Avantor® Reports Fourth Quarter and Full-Year 2021 Results
2022-01-21 21:05 ET
Avantor® Declares Dividend on Mandatory Convertible Preferred Stock
2022-01-18 21:05 ET
Avantor® to Report Fourth Quarter and Full Year 2021 Results and Host Earnings Call on February 4, 2022
2022-01-05 15:36 ET
Greg Mayer Joins Argosy Healthcare Partners
2021-12-22 14:17 ET
CORRECTING AND REPLACING: Avantor to Participate in the 40th Annual J.P. Morgan Healthcare Conference
2021-12-15 14:05 ET
Avantor® Opens Single-Use Logistics Hub to Strengthen Global Biopharma Supply Chain
2021-12-14 14:05 ET
Avantor® to Participate in the 40th Annual J.P. Morgan Healthcare Conference
2021-12-06 01:00 ET
Avantor Provides Critical Personal Protection Supplies to Vulnerable Populations through NGOs
2021-11-15 21:05 ET
Avantor® to Participate in the Evercore ISI 4th Annual HealthCONx Conference
2021-11-01 13:24 ET
Avantor® Completes Acquisition of Masterflex®
2021-10-28 20:05 ET
Avantor® Reports Third Quarter 2021 Results
2021-10-28 13:03 ET
Avantor® Opens Second European Single-use Facility in the Netherlands; Supports Growing Demand for Bioproduction
2021-10-21 20:10 ET
Avantor® Declares Dividend on Mandatory Convertible Preferred Stock
2021-10-19 21:52 ET
Avantor® Announces Pricing of Offering of $800 Million of Senior Notes
2021-10-19 11:33 ET
Avantor® Announces Offering of Senior Notes
2021-10-12 10:47 ET
Avantor® Announces Preliminary Third Quarter Unaudited Revenues
2021-09-28 10:37 ET
Avantor® to Report Third Quarter 2021 Earnings and Host Earnings Call on Friday, October 29, 2021
2021-09-13 10:14 ET
Avantor® Announces Offering of Common Stock
2021-09-07 10:30 ET
Avantor® to Acquire Masterflex®; Expands Proprietary Single-Use Offering for Bioproduction
2021-08-31 12:25 ET
Avantor® Announces Investment in Hydration Capabilities to Address Growing Demand for Biologics
2021-08-30 20:11 ET
Avantor® to Host Virtual Investor Day
2021-07-29 20:05 ET
Avantor® Reports Second Quarter 2021 Results
2021-07-22 13:25 ET
Avantor® Publishes Inaugural Sustainability Report; Drives Positive Impact through Science for Goodness Platform
2021-07-20 12:25 ET
Avantor® Declares Dividend on Mandatory Convertible Preferred Stock
2021-07-16 12:25 ET
Avantor® Announces Date Change for Second Quarter 2021 Earnings Release and Conference Call
2021-07-06 13:06 ET
Avantor® to Report Second Quarter 2021 Earnings and Host Earnings Call on Wednesday, July 28, 2021
2021-06-25 00:41 ET
Avantor Named Best Company in Bioprocessing Excellence for Single-use Solutions and Best Bioprocessing Supplier for Upstream Processing at Biologics Manufacturing Korea 2021
2021-06-10 20:05 ET
Avantor® Completes Acquisition of Ritter GmbH and its Affiliates
2021-06-01 20:05 ET
Avantor® Acquires RIM Bio; Expands Bioproduction Footprint into China
2021-05-31 21:00 ET
Avantor Acquires RIM Bio; Expands Bioproduction Footprint into China
2021-05-19 20:05 ET
Avantor® to Present at Goldman Sachs 42nd Annual Global Healthcare Conference
2021-04-28 20:05 ET
Avantor® Reports First Quarter 2021 Results
2021-04-27 20:05 ET
Avantor® to Present at BofA Securities 2021 Virtual Health Care Conference
2021-04-26 17:26 ET
Avantor® to Boost Global Production of Single­-Use Technologies and Address Growing Biopharma Demand
2021-04-21 20:05 ET
/C O R R E C T I O N -- Avantor and Financial News/
2021-04-12 11:05 ET
Avantor® to Acquire Ritter GmbH and its Affiliates; Expands Proprietary Offering for Diagnostic and Drug Discovery Workflows
2021-04-06 04:29 ET
Avantor Named Best Bioprocessing Supplier in Single-Use Manufacturing at Asia-Pacific Bioprocessing Excellence Awards 2021
2021-03-31 20:05 ET
Avantor® to Report First Quarter 2021 Earnings and Host Earnings Call on Wednesday, April 28, 2021
2021-03-18 20:21 ET
Avantor® Announces Credit Rating Upgrade by Moody's Investors Services
2021-02-22 23:03 ET
Avantor® to Participate at the Raymond James 42nd Annual Institutional Investor Conference
2021-02-10 13:37 ET
Avantor® Announces Credit Rating Upgrade by S&P Global Ratings
2021-02-03 21:05 ET
Avantor® Reports Fourth Quarter and Full-Year 2020 Results
2021-01-21 21:05 ET
Avantor® Declares Dividend on Mandatory Convertible Preferred Stock
2021-01-11 21:05 ET
Avantor® to Report Fourth Quarter and Full Year 2020 Earnings and Host Earnings Call on Wednesday, February 3, 2021
2021-01-11 11:01 ET
Avantor® Announces Preliminary Fourth Quarter Unaudited Revenues and Estimated Free Cash Flow
2020-12-17 13:37 ET
Avantor® Sets Science in Motion for Goodness with Donations and Grants to Community-Based Organizations
2020-12-14 13:37 ET
Avantor® to Present at the 39th Annual J.P. Morgan Healthcare Conference
2020-11-23 13:37 ET
Avantor® to Participate at the Evercore ISI 3rd Annual HealthCONx Virtual Conference
2020-11-19 13:37 ET
Avantor® Opens New Biorepository Facility in Europe to Support Growing Demand for Scientific Research and Clinical Trial Sample Storage
2020-11-11 13:37 ET
Avantor® to Present at the Jefferies Virtual London Healthcare Conference
2020-11-06 03:07 ET
Avantor® Announces Pricing of Upsized Secondary Offering
2020-11-04 21:05 ET
Avantor® Announces Secondary Offering of 71,339,001 Shares of Common Stock
2020-11-02 13:37 ET
Avantor® Discusses Cell & Gene Therapy Production Trends Through the Lens of COVID-19
2020-10-30 20:05 ET
Avantor® Announces Upsizing and Pricing of Offering of €650.0 Million of Senior First Lien Notes
2020-10-28 11:37 ET
Avantor® Announces Offering of Senior First Lien Notes
2020-10-27 20:05 ET
Avantor® Reports Third Quarter 2020 Results and Announces Time Change for Earnings Call
2020-10-23 12:01 ET
Avantor® Announces Preliminary Third Quarter Unaudited Revenues
2020-10-21 20:05 ET
Avantor® Declares Dividend on Mandatory Convertible Preferred Stock
2020-10-21 12:37 ET
Avantor® Discusses Supply Chain Readiness at 2020 World Vaccine Congress Europe
2020-10-08 12:37 ET
Avantor's General Counsel Justin Miller Honored as "Legend in Law" by The Burton Awards Program
2020-10-02 13:05 ET
Avantor® to Report Third Quarter Earnings and Host Earnings Call on Wednesday, October 28, 2020
2020-09-22 13:05 ET
Avantor® Appoints Frederic Vanderhaegen Executive Vice President, Americas and Europe
2020-09-01 12:05 ET
Avantor® to Present at the Morgan Stanley Virtual Healthcare Conference
2020-08-31 13:25 ET
Avantor® to Present at the 2020 Wells Fargo Virtual Healthcare Conference
2020-08-20 12:31 ET
Avantor® Announces Pricing of Upsized Secondary Offering
2020-08-19 20:14 ET
Avantor® Announces Secondary Offering of 38,500,000 Shares of Common Stock
2020-08-10 12:01 ET
Avantor Announces Credit Rating Upgrade by S&P Global Ratings
2020-07-29 20:05 ET
Avantor® Reports Second Quarter 2020 Results
2020-07-21 20:05 ET
Avantor® Declares Dividend on Mandatory Convertible Preferred Stock
2020-07-07 20:15 ET
Avantor® Announces Upsizing and Pricing of Offering of $2.0 Billion Equivalent of Senior Notes
2020-07-07 07:50 ET
Avantor® Announces Preliminary Second Quarter 2020 Unaudited Revenue
2020-07-07 07:45 ET
Avantor® Announces Offering of Senior Notes
2020-07-01 20:05 ET
Avantor® to Report Second Quarter Earnings and Host Earnings Call on Wednesday, July 29, 2020
2020-06-30 12:25 ET
Avantor® Expands Life Sciences Innovation Center to Address Bioprocessing Needs in Protein Science, Monoclonal Antibodies (mAbs), Cell and Gene Therapy
2020-06-23 12:25 ET
Avantor® Named to Fortune 500 List
2020-05-26 20:05 ET
Avantor® Announces Closing of Secondary Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
2020-05-22 14:40 ET
Avantor Announces Credit Rating Upgrade by Fitch Ratings
2020-05-21 02:33 ET
Avantor® Announces Pricing of Secondary Offering
2020-05-18 20:05 ET
Avantor® Announces Secondary Offering of 45,000,000 Shares of Common Stock
2020-05-06 13:01 ET
Avantor to Present at the Virtual Bank of America Securities 2020 Healthcare Conference
2020-04-29 20:05 ET
Avantor Reports First Quarter 2020 Results
2020-04-23 13:54 ET
Avantor® and the Avantor Foundation Provide Support to Address Coronavirus (COVID-19) Pandemic
2020-04-21 20:05 ET
Avantor® Declares Dividend on Mandatory Convertible Preferred Stock
2020-04-03 20:10 ET
Avantor® to Report First Quarter 2020 Earnings and Host Earnings Call on Wednesday, April 29, 2020
2020-03-23 10:08 ET
Avantor® Appoints Tommy Thomas as Vice President, Investor Relations
2020-03-18 12:37 ET
Avantor® Launches New Protein A Chromatography Resin - PROchievA - that Provides Supply Chain Flexibility and Improves Downstream Purification Performance for Monoclonal Antibodies (mAbs) Production
2020-02-18 21:05 ET
Avantor® to Participate in Cowen and Company's 40th Annual Health Care Conference
2020-02-07 11:00 ET
Avantor Reports Fourth Quarter and Full-Year 2019 Results
2020-01-24 21:23 ET
Avantor® to Report Fourth Quarter and Full Year 2019 Earnings and Host Earnings Call on Friday, February 7
2020-01-21 21:05 ET
Avantor® Declares Dividend on Mandatory Convertible Preferred Stock
2020-01-02 18:41 ET
Avantor® to Participate in the J.P. Morgan Healthcare Conference
2019-11-25 14:12 ET
Avantor® to Participate in the Evercore ISI HealthCONx Conference
2019-11-06 16:29 ET
Avantor® and NIBRT Collaborate to Advance Bioprocessing by Addressing Downstream Bottlenecks in Monoclonal Antibodies (mAbs) Production
2019-11-05 11:00 ET
Avantor Reports Third Quarter 2019 Results
2019-10-22 20:05 ET
Avantor® to Report Third Quarter Earnings and Host Earnings Call on Tuesday, November 5
2019-10-21 20:05 ET
Avantor® Declares Dividend on Mandatory Convertible Preferred Stock

SEC forms

Show financial reports only

SEC form 10
2024-04-26 09:00 ET
Avantor published news for 2024 q1
SEC form 8
2024-04-26 06:20 ET
Avantor published news for 2024 q1
SEC form 8
2024-04-26 06:20 ET
Avantor reported for 2024 q1
SEC form 10
2024-04-26 00:00 ET
Avantor published news for 2024 q1
SEC form 8
2024-02-14 00:00 ET
Avantor published news for 2023 q4
SEC form 10
2024-02-14 00:00 ET
Avantor reported for 2023 q4
SEC form 8
2024-02-14 00:00 ET
Avantor published news for 2023 q4
SEC form 8
2024-02-14 00:00 ET
Avantor published news for 2023 q4
SEC form 10
2023-10-27 09:11 ET
Avantor published news for 2023 q3
SEC form 8
2023-10-27 06:11 ET
Avantor reported for 2023 q3
SEC form 10
2023-10-27 00:00 ET
Avantor published news for 2023 q3
SEC form 10
2023-07-28 09:06 ET
Avantor published news for 2023 q2
SEC form 6
2023-07-28 06:10 ET
Avantor reported for 2023 q2
SEC form 10
2023-07-28 00:00 ET
Avantor published news for 2023 q2
SEC form 8
2023-07-28 00:00 ET
Avantor published news for 2023 q2
SEC form 6
2023-07-13 08:38 ET
Avantor published news for 2023 q2
SEC form 6
2023-07-05 16:31 ET
Avantor published news for 2023 q2
SEC form 8
2023-04-28 00:00 ET
Avantor published news for 2023 q1
SEC form 10
2023-04-28 00:00 ET
Avantor published news for 2023 q1
SEC form 10
2023-02-14 00:00 ET
Avantor reported for 2022 q4
SEC form 8
2023-02-03 00:00 ET
Avantor reported for 2022 q4
SEC form 10
2022-10-28 00:00 ET
Avantor reported for 2022 q3
SEC form 8
2022-10-28 00:00 ET
Avantor reported for 2022 q3
SEC form 10
2022-07-29 00:00 ET
Avantor reported for 2022 q2
SEC form 8
2022-07-28 00:00 ET
Avantor reported for 2022 q2
SEC form 10
2022-04-29 00:00 ET
Avantor reported for 2022 q1
SEC form 8
2022-04-28 00:00 ET
Avantor reported for 2022 q1
SEC form 10
2022-02-11 00:00 ET
Avantor published news for 2021 q4
SEC form 8
2022-02-03 00:00 ET
Avantor published news for 2021 q4
SEC form 10
2021-10-29 00:00 ET
Avantor published news for 2021 q3
SEC form 8
2021-10-28 00:00 ET
Avantor published news for 2021 q3
SEC form 8
2021-10-12 00:00 ET
Avantor published news for 2021 q3
SEC form 10
2021-07-30 00:00 ET
Avantor published news for 2021 q2
SEC form 8
2021-07-29 00:00 ET
Avantor published news for 2021 q2
SEC form 10
2021-04-28 00:00 ET
Avantor published news for 2021 q1
SEC form 8
2021-04-28 00:00 ET
Avantor published news for 2021 q1